Agile Therapeutics Inc. Stock
Your prediction
Agile Therapeutics Inc. Stock
Our community identified positive and negative aspects for Agile Therapeutics Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Agile Therapeutics Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Agile Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agile Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agile Therapeutics Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 5.840% | -31.089% | -20.320% | -73.274% | -73.178% | -79.946% | -96.948% |
| Evolus Inc | -1.850% | 35.230% | 25.286% | 50.500% | 32.550% | -18.831% | -21.049% |
| Rhythm Pharmaceuticals | 3.590% | 1.047% | 1.579% | 21.384% | 3.209% | 295.492% | 710.924% |
Comments
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat